Given that overexpression of DDAH has an ADMA-lowering effect and improves diabetes-related endothelial dysfunction [31], our data further suggest that restoration of DDAH activity may be a therapeutic target in diabetes-associated programming. This evidence concerns the gene DDAH1 and endothelial dysfunction.